You just read:

Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases

News provided by

Ridgeback Biotherapeutics LP

Dec 13, 2018, 11:34 ET